Literature DB >> 12119038

SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities.

David De Souza1, Louis J Fabri, Andrew Nash, Douglas J Hilton, Nicos A Nicola, Manuel Baca.   

Abstract

Suppressor of cytokine signaling-3 (SOCS-3) and the protein tyrosine phosphatase SHP-2 both regulate signaling by cytokines of the interleukin-6 family, and this is dependent upon recruitment to tyrosine 757 in the shared cytokine receptor subunit gp130. To better explore the overlap in ligand binding specificities exhibited by these two signaling regulators, we have mapped the phosphopeptide binding preferences of the SH2 domains from SOCS-3 and SHP-2. Degenerate phosphopeptide libraries were screened against recombinantly produced SH2 domains to determine the sequences of optimal phosphopeptide ligands. We found that the consensus ligand binding motif for SOCS-3 was pY-(S/A/V/Y/F)-hydrophobic-(V/I/L)-hydrophobic-(H/V/I/Y), while the consensus motif for SHP-2 was pY-(S/T/A/V/I)-X-(V/I/L)-X-(W/F). We validated these data through the design of phosphopeptide ligands based on the consensus motifs and found that these bound to SOCS-3 and SHP-2 with high affinity. Finally, we have compared the affinity of SOCS-3 for binding to phosphopeptides representing putative docking sites in the gp130, leptin and erythropoietin receptors. While SOCS-3 binds with much higher affinity to a gp130 phosphopeptide than to phosphopeptides derived from the other receptors, multiple SOCS-3 binding sites are predicted to exist in the leptin and erythropoietin receptors which may compensate for weaker binding to individual sites.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12119038     DOI: 10.1021/bi0259507

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  39 in total

1.  Simple method for determination of the number of Helicobacter pylori CagA variable-region EPIYA tyrosine phosphorylation motifs by PCR.

Authors:  Richard H Argent; Youli Zhang; John C Atherton
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

Review 2.  Negative regulation of cytokine signaling.

Authors:  Akihiko Yoshimura
Journal:  Clin Rev Allergy Immunol       Date:  2005-06       Impact factor: 8.667

Review 3.  Molecular and neural mediators of leptin action.

Authors:  Scott A Robertson; Gina M Leinninger; Martin G Myers
Journal:  Physiol Behav       Date:  2008-04-13

Review 4.  Protein tyrosine phosphatases in the JAK/STAT pathway.

Authors:  Dan Xu; Cheng-Kui Qu
Journal:  Front Biosci       Date:  2008-05-01

Review 5.  SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?

Authors:  R Mahony; S Ahmed; C Diskin; N J Stevenson
Journal:  Cell Mol Life Sci       Date:  2016-05-02       Impact factor: 9.261

Review 6.  Inhibition of IL-6 family cytokines by SOCS3.

Authors:  Jeffrey J Babon; Leila N Varghese; Nicos A Nicola
Journal:  Semin Immunol       Date:  2014-01-10       Impact factor: 11.130

Review 7.  H. pylori infection, inflammation and gastric cancer.

Authors:  Qurteeba Qadri; Roohi Rasool; G M Gulzar; Sameer Naqash; Zafar A Shah
Journal:  J Gastrointest Cancer       Date:  2014-06

8.  JAK2 and SHP2 reciprocally regulate tyrosine phosphorylation and stability of proapoptotic protein ASK1.

Authors:  Luyang Yu; Wang Min; Yun He; Lingfeng Qin; Haifeng Zhang; Anton M Bennett; Hong Chen
Journal:  J Biol Chem       Date:  2009-03-13       Impact factor: 5.157

Review 9.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

10.  Mechanism of attenuation of leptin signaling under chronic ligand stimulation.

Authors:  Holger Knobelspies; Julia Zeidler; Paul Hekerman; Simone Bamberg-Lemper; Walter Becker
Journal:  BMC Biochem       Date:  2010-01-08       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.